Abstract
Recent studies have demonstrated benefits of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in the management of heart failure with reduced ejection fraction (HFrEF). Although current literature postulates several salient effects, the primary mechanism is unclear. Intriguingly, benefit is seen rapidly. Improved myocardial energetics and substrate efficiency through Na+/H+ exchanger inhibition and increased β-hydroxybutyrate metabolism may rapidly reduce myocardial work.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
